26
Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins Introduction to Clinical Pharmacology Chapter 29- Antiparkinsonism Drugs

Ppt chapter029

Embed Size (px)

Citation preview

Page 1: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Introduction to Clinical Pharmacology

Chapter 29-Antiparkinsonism Drugs

Page 2: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Dopaminergic Drugs: Actions Dopaminergic Drugs: Actions

• Symptoms of parkinsonism are caused by depletion of dopamine in CNS

• Amantadine: make more of dopamine available at receptor site; Selegiline: inhibits monoamine oxidase type B, again making more dopamine available

• Combining levodopa with another drug allows more levodopa to reach brain hence provide better pharmacologic effect in patients with Parkinson’s disease

change "patient" to "client"
Page 3: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Dopaminergic Drugs: Uses Dopaminergic Drugs: Uses

• Dopaminergic drugs are used to treat:

– Parkinson’s disease

– Parkinson-like symptoms as a result of injury, drug therapy, or encephalitis

– Restless leg syndrome

– Viral infections

Page 4: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Dopaminergic Drugs: Adverse Reactions, Contraindications, and PrecautionDopaminergic Drugs: Adverse Reactions, Contraindications, and Precaution

• Dry mouth, difficulty in swallowing, anorexia, nausea, and vomiting, abdominal pain, constipation, increased hand tremor headache, dizziness

• Adverse reactions seen with levodopa: choreiform movements, dystonic movements

• Contraindications:

– Dopaminergic drugs: Patients with known hypersensitivity to the drugs

change "patient" to "client"
Page 5: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Dopaminergic Drugs: Adverse Reaction Contraindications And Precautions (cont’d)

Dopaminergic Drugs: Adverse Reaction Contraindications And Precautions (cont’d)

– Levodopa: Patients with narrow-angle glaucoma, and those receiving MAOI antidepressants

• Precautions:

– Levodopa is used cautiously in patients with cardiovascular or pulmonary diseases; peptic ulcer disease; renal or hepatic disease; and psychosis

– Dopamine agonist, selegiline, should not be used with opioid meperidine due to antimetabolite conversion

change "patient" to "client"
Page 6: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Dopaminergic Drugs: InteractionsDopaminergic Drugs: Interactions

Interactant Drug Effect of Interaction

Tricyclic antidepressants Increased risk of hypertension and dyskinesia

Antacids Increased effect of levodopa

Anticonvulsants Decreased effect of levodopa

Page 7: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Cholinergic Blocking Drugs Anticholinergics: Actions Cholinergic Blocking Drugs Anticholinergics: Actions

• Drugs with cholinergic blocking activity, block Ach in CNS enhancing dopamine transmission

• Antihistimines, such as diphenhydramine are used in elderly patients as they produce fewer adverse effects

change "patient" to 'client"
Page 8: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Cholinergic Blocking Drugs Anticholinergics: Uses and Adverse Reactions

Cholinergic Blocking Drugs Anticholinergics: Uses and Adverse Reactions• Uses:

– Used as adjunctive therapy in all forms of parkinsonism and in control of drug-induced extrapyramidal disorders

• Adverse Reactions:

– Dry mouth; blurred vision; dizziness; mild nausea; nervousness; skin rash; urticaria; urinary retention; dysuria; tachycardia; muscle weakness; disorientation; confusion

Page 9: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Cholinergic Blocking Drugs Anticholinergics: Contraindications and PrecautionsCholinergic Blocking Drugs Anticholinergics: Contraindications and Precautions

• Contraindicated in patients :

– With hypersensitivity to anticholinergic drugs; those with glaucoma; pyloric or duodenal obstruction; peptic ulcers; prostatic hypertrophy; achalasia; myasthenia gravis; megacolon

• Used with caution in patients with:

– Tachycardia; cardiac arrhythmias; hypertension; hypotension; those with a tendency toward urinary retention; those with decreased liver or kidney function; with obstructive disease of urinary system or gastrointestinal tract

change "patient" to "client"
Page 10: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Cholinergic Blocking Drugs Anticholinergics: InteractionsCholinergic Blocking Drugs Anticholinergics: Interactions

Interactant drug Effect of interaction

Amantadine Increasedanticholinergic effects

Digoxin Increased digoxin serum levels

Haloperidol Increased psychotic behavior

Phenothiazines Increased anticholinergic effects

Page 11: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

COMT Inhibitors: Actions and Uses COMT Inhibitors: Actions and Uses

• Actions:

– Prolong the effect of levodopa by blocking an enzyme, catechol-O-methyltransferase, which eliminates dopamine

– With levodopa- increased plasma concentration and duration of action of levodopa

• Uses:

– COMT inhibitors are used as adjuncts to levodopa/carbidopa in treating Parkinson’s disease

Page 12: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

COMT Inhibitors: Adverse Reactions, Contraindications And Precautions COMT Inhibitors: Adverse Reactions, Contraindications And Precautions

• Dizziness, dyskinesias, hyperkinesias, nausea, anorexia, and diarrhea, orthostatic hypotension, sleep disorders, excessive dreaming, somnolence, and muscle cramps, liver failure

• Contraindicated: Patients with hypersensitivity to drugs, during pregnancy and lactation

• Caution: Patients with hypertension; hypotension; decreased hepatic or renal function

change "patient" to "client"
Page 13: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

COMT Inhibitors: InteractionsCOMT Inhibitors: Interactions

Interactant Drug Effect of Interaction

MAOI antidepressants Increased risk of toxicity of both drugs

Adrenergic drugs Increased risk of cardiac symptoms

Page 14: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Dopamine Receptor Agonists: Actions and Uses Dopamine Receptor Agonists: Actions and Uses

• Actions:

– Act directly on postsynaptic dopamine receptors of nerve cells in brain, mimicking effects of dopamine in brain

• Uses:

– Used for treatment of signs and symptoms of Parkinson’s disease

Page 15: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Dopamine Receptor Agonists: Adverse Reactions, Contraindication, Precautions Dopamine Receptor Agonists: Adverse Reactions, Contraindication, Precautions

• Nausea; dizziness; vomiting; somnolence; hallucinations; confusion; visual disturbances; postural hypotension; abnormal involuntary movements; headache

• Contraindications: Patients with known hypersensitivity to drugs

• Precautions: Used with caution in patients with: dyskinesia; orthostatic hypotension; hepatic or renal impairment; patients with history of hallucinations or psychosis; cardiovascular disease; renal impairment

change "patient" to "client"
Page 16: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Dopamine Receptor Agonists: InteractionsDopamine Receptor Agonists: InteractionsInteractant Drug Effect of Interaction

Cimetidine, ranitidine Increased agonist effectiveness

Verapamil, quinidine Increased agonist effectiveness

Estrogen Increased agonist effectiveness

Phenothiazines Decreased agonist effectiveness

Page 17: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Process: Assessment Nursing Process: Assessment • Preadministration assessment:

– Obtains health history from family member

– Performs physical assessment of patient to provide baseline for future evaluations of drug therapy

• Ongoing assessment:

– Evaluate patient’s response to drug therapy by observing patients for various neuromuscular signs and compare these observations with data obtained during initial physical assessment

change "patient" to "client"
Page 18: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Process: Planning Nursing Process: Planning

• Expected outcomes for patient may include:

– Optimal response to drug therapy

– Support of patient needs related to management of adverse reactions

– Absence of injury

– Understanding of and compliance with prescribed therapeutic regimen

change "patient" to "client"
Page 19: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Process: Implementation Nursing Process: Implementation

• Promoting an optimal response to therapy:

– Carefully monitor drug therapy; provide psychological support; emphasize patient and family teaching

– Requires titration of doses based on patient activities

– Withhold next dose of drug and immediately notify primary health care provider if sudden behavioral changes are noted

change "patient" to "client"
Page 20: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Process: ImplementationNursing Process: Implementation

• Monitoring and managing patient needs:

– Imbalanced nutrition: Less than bodily requirements

•Help patient relieve dry mouth by offering frequent sips of water, ice chips, or hard candy

•Create calm environment; serve small frequent meals; serve foods patient prefers to help improve nutrition

•Monitor patient’s weight daily

change "patient" to "client"
Page 21: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Process: ImplementationNursing Process: Implementation

• Monitoring and Managing Patient Needs (cont’d):

– Constipation:

•Observe patient with parkinsonism for outward changes that may indicate one or more adverse reactions

•Stress need for diet high in fiber and increasing fluids in diet

change "patient" to "client"
Page 22: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Process: ImplementationNursing Process: Implementation

• Monitoring and managing patient needs (cont’d):

– Risk for injury:

•Carefully evaluates any sudden changes in patient’s behavior or activity and reports them to primary health care provider

•Assist patient in getting out of bed or a chair, walking, and other self-care activities

change "patient" to "client"
Page 23: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Process: ImplementationNursing Process: Implementation

• Monitoring and managing patient needs (cont’d):

– Impaired physical mobility:

• If the symptoms occur primary health care provider may order a drug holiday that includes complete withdrawal of levodopa for 5 to 14 days, followed by gradually restarting drug therapy at lower dose

change "patient" to "client"
Page 24: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Process: ImplementationNursing Process: Implementation

• Educating the patient and family:

– Evaluate patient’s ability to understand therapeutic drug regimen; ability to perform self-care in the home environment; ability to comply with prescribed drug therapy

– Encourages family to create a home environment that is least likely to result in accidents or falls

change "patient" to "client"
Page 25: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Process: Evaluation Nursing Process: Evaluation

• Therapeutic effect is achieved and the symptoms of parkinsonism are controlled

• Adverse reactions are identified, reported, and managed successfully through appropriate nursing interventions

• No evidence of injury is seen

• Patients verbalizes an understanding of treatment modalities, adverse reactions, and importance of continued follow-up care

• Patients and family demonstrate an understanding of drug regimen

change "patient" to "client"
Page 26: Ppt chapter029

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

End of Presentation